Government
Project NextGen enlists ex-Warp Speed vaccine leader’s biotech for Covid-19 antibodies
The former leader of Operation Warp Speed’s vaccines effort, which led to a quick rollout of Covid jabs, is getting federal funding for his biotech’s…

The former leader of Operation Warp Speed’s vaccines effort, which led to a quick rollout of Covid jabs, is getting federal funding for his biotech’s work on the next generation of Covid therapeutics.
As part of the US government’s $5 billion Project NextGen, John Mascola’s ModeX Therapeutics will receive an initial $59 million to get a multispecific antibody into and through a Phase I trial as a potential tool for thwarting future SARS-CoV-2 variants. Mascola joined the OPKO Health-owned ModeX in 2022 as chief scientific officer after steering Warp Speed’s vaccine work and serving as director of the NIH’s Vaccine Research Center.
BARDA is placing its bet on a biotech flush with former US scientific leaders. ModeX co-founder and OPKO vice chair Elias Zerhouni was NIH director in the early aughts. The Natick, MA-based biotech is led by Gary Nabel, who was the first director of the Vaccine Research Center and then spent about eight years at Sanofi, where he was scientific chief until 2020.
The investigational antibodies will likely enter the clinic during 2025, Nabel, the CEO and president, told Endpoints News.
“What we’re trying to do here, too, is not only make it fast, but as a prototype we’re also trying to do it in a way where we can get good yields,” Nabel said. “Because if you can get good yields, it helps to make it more translatable in a real-world setting. It’ll decrease the cost of goods. It makes it much more practical. If our goal was simply just to go fast, nowadays you can probably, with the right signals from FDA, you probably can do it in six months.”
ModeX is working on putting together four to six independent antibody binding sites in one molecule. The research will include work on mRNA or DNA vectors for delivery, ModeX said.
Regeneron, meanwhile, is getting about $326 million as part of Project NextGen to make a Covid-19 monoclonal antibody. Gritstone bio is also receiving funds under the project for a Phase IIb trial of its Covid-19 vaccine.
ModeX, with the multispecific approach, hopes to “shut off routes of escape” and “cover more variants of the virus,” Nabel said.
Other antibodies had received the FDA’s emergency use greenlight but were later revoked after variants proved them ineffective, such as Eli Lilly’s bebtelovimab and Vir Biotechnology’s sotrovimab. Other biotechs are looking at creating antibody treatments for future variants and long Covid, like Aerium Therapeutics.
Up to another $109 million could come ModeX’s way if the biotech meets certain benchmarks developing multispecific antibodies against influenza and other viral pathogens, the company said Sept. 28. ModeX also lined up a deal with Merck on an Epstein-Barr vaccine set to enter clinical testing next year, Nabel told Endpoints at the time of the March disclosure. ModeX is also working on HIV and oncology programs.
us government vaccine testing fda antibodies dna covid-19International
Fighting the Surveillance State Begins with the Individual
It’s a well-known fact at this point that in the United States and most of the so-called free countries that there is a robust surveillance state in…

Government
Forget Ron DeSantis: Walt Disney has a much bigger problem
The company’s political woes are a sideshow to the one key issue Bob Iger has to solve.

Walt Disney has a massive, but solvable, problem.
The company's current skirmishes with Florida Gov. DeSantis get a lot of headlines, but they're not having a major impact on the company's bottom line.
Related: What the Bud Light boycott means for Disney, Target, and Starbucks
DeSantis has made Walt Disney (DIS) - Get Free Report a target in what he calls his war on woke, an effort to win right-wing support as he tries to secure the Republican Party nomination for president.
That effort has generated plenty of press and multiple lawsuits tied to the governor's takeover of the former Reedy Creek Improvement District, Disney's legislated self-governance operation. But it has not hurt revenue at the company's massive Florida theme-park complex.
Disney Chief Executive Bob Iger addressed the matter during the company's third-quarter-earnings call, without directly mentioning DeSantis.
"Walt Disney World is still performing well above precovid levels: 21% higher in revenue and 29% higher in operating income compared to fiscal 2019," he said.
And "following a number of recent changes we've implemented, we continue to see positive guest-experience ratings in our theme parks, including Walt Disney World, and positive indicators for guests looking to book future visits."
The theme parks are not Disney's problem. The death of the movie business is, however, a hurdle that Iger has yet to show that the company has a plan to clear.
Image source: Walt Disney
Disney needs a plan to monetize content
In 2019 Walt Disney drew in more $11 billion in global box office, or $13 billion when you add in the former Fox properties it also owns. In that year seven Mouse House films crossed the billion-dollar threshold in theaters, according to data from Box Office Mojo.
This year, the company will struggle to reach half that and it has no billion-dollar films, with "Guardians of the Galaxy Vol. 3" closing its theatrical run at $845 million globally.
(That's actually good for third place this year, as only "Barbie" and "The Super Mario Bros. Movie" have broken the billion-dollar mark and they may be the only two films to do that this year.)
In the precovid world Disney could release two Pixar movies, three Marvel films, a live-action remake of an animated classic, and maybe one other film that each would be nearly guaranteed to earn $1 billion at the box office.
That's simply not how the movie business works anymore. While theaters may remain part of Disney's plan to monetize its content, the past isn't coming back. Theaters may remain a piece of the movie-release puzzle, but 2023 isn't an anomaly or a bad release schedule.
Consumers have big TVs at home and they're more than happy to watch most films on them.
Disney owns the IP but charges too little
People aren't less interested in Marvel and Star Wars; they're just getting their fix from Disney+ at an absurdly low price.
Over the past couple of months through the next few weeks, I will have watched about seven hours of premium Star Wars content and five hours of top-tier Marvel content with "Ahsoka" and "Loki" respectively.
Before the covid pandemic, I gladly would have paid theater prices for each movie in those respective universes. Now, I have consumed about six movies worth of premium content for less than the price of two movie tickets.
By making its premium content television shows available on a service that people can buy for $7.99 a month Disney has devalued its most valuable asset, its intellectual property.
Consumers have shown that they will pay the $10 to $15 cost of a movie ticket to see what happens next in the Marvel Cinematic Universe or the Star Wars galaxy. But the company has offered top-tier content from those franchises at a lower price.
Iger needs to find a way to replace billions of dollars in lost box office, but charging less for the company's content makes no sense.
Now, some fans likely won't pay triple the price for Disney+. But if it were to bundle a direct-to-consumer ESPN along with content that currently gets released to movie theaters, Disney might create a package that it can price in a way that reflects the value of its IP.
Consumers want Disney's content and they will likely pay more for it. Iger simply has to find a way to make that happen.
Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.
governorInternational
Stock Market Today: Stocks turn higher as Treasury yields retreat; big tech earnings up next
A pullback in Treasury yields has stocks moving higher Monday heading into a busy earnings week and a key 2-year bond auction later on Tuesday.

- Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.
-
International5 hours ago
A further examination of the state of the economic tailwind
-
Uncategorized3 hours ago
California bill aims to cap crypto ATM withdrawals at $1K per day to combat scams
-
Uncategorized5 hours ago
Bitcoin ETF to trigger massive demand from institutions, EY says
-
Uncategorized24 hours ago
Jeff Bezos and Bill Gates-backed billion dollar business closes
-
Uncategorized23 hours ago
Bearish Triad: Stock Market Indexes and Market Breadth Test Important Support Level; VIX Above 20
-
Uncategorized3 hours ago
Bitcoin price must break $31K to avoid 2023 ‘bearish fractal’
-
International3 hours ago
Stock Market Today: Stocks turn higher as Treasury yields retreat; big tech earnings up next
-
Uncategorized3 hours ago
An airline just launched one of the country’s longest domestic flights